Anti-EGFRs confer overall survival gain in RAS wild-type mCRC.
Anti-EGFRs provide clear benefit in PFS and ORR when added to chemotherapy alone.
Anti-EGFRs provide benefit in OS but not PFS and ORR versus chemotherapy plus bevacizumab.
Both anti-EGFRs and bevacizumab are valid first-line options in RAS wild-type patients.
Further translational studies are needed for the goal of treatment personalization.